pyrrolidine has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Askri, M; Boudriga, S; Brieger, L; Cheurfa, M; Hamden, K; Knorr, M; Sobeh, M; Strohmann, C; Toumi, A | 1 |
| Gupta, M; Kaur, P; Kumar, M; Sharma, M; Singh, D | 1 |
2 other study(ies) available for pyrrolidine and Alloxan Diabetes
| Article | Year |
|---|---|
Synthesis, antidiabetic activity and molecular docking study of rhodanine-substitued spirooxindole pyrrolidine derivatives as novel α-amylase inhibitors.
Topics: Alloxan; alpha-Amylases; Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Male; Molecular Structure; Oxindoles; Pyrrolidines; Rats; Rats, Wistar; Spiro Compounds; Structure-Activity Relationship | 2021 |
Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors.
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Halogenation; Humans; Hypoglycemic Agents; Male; Models, Molecular; Molecular Docking Simulation; Pyrrolidines; Rats; Rats, Wistar | 2013 |